Intellia Therapeutics, Inc. (NTLA) Stock Grade

About Intellia Therapeutics, Inc.'s fundamentals

Intellia Therapeutics is a biotechnology company with a market capitalization of $974.3 million that has demonstrated revenue growth of 16.9% year-over-year, indicating expanding business activity. However, the company operates at a significant loss, with a net margin of -609.9%, meaning it spent substantially more than it generated in revenue during its latest annual period and reported a net loss. The company does not pay a dividend. These metrics are typical of early-stage biotech firms investing heavily in research and development before achieving profitability.